Litigation Details for ALKERMES, INC. v. TEVA PHARMACEUTICAL INDUSTRIES USA,INC (D.N.J. 2020)

✉ Email this page to a colleague

ALKERMES, INC. v. TEVA PHARMACEUTICAL INDUSTRIES USA,INC (D.N.J. 2020)

Docket	⤷ Start Trial	Date Filed	2020-09-09
Court	District Court, D. New Jersey	Date Terminated	2023-08-30
Cause	28:1338 Patent Infringement	Assigned To	Madeline Cox Arleo
Jury Demand	None	Referred To	Michael A. Hammer
Parties	TEVA PHARMACEUTICALS USA, INC.
Patents	6,264,987; 7,919,499
Attorneys	CHARLES MICHAEL LIZZA
Firms	Kean University
Link to Docket	External link to docket

Small Molecule Drugs cited in ALKERMES, INC. v. TEVA PHARMACEUTICAL INDUSTRIES USA,INC

The small molecule drugs covered by the patents cited in this case are ⤷ Start Trial and ⤷ Start Trial .

Details for ALKERMES, INC. v. TEVA PHARMACEUTICAL INDUSTRIES USA,INC (D.N.J. 2020)

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Date Filed	Document No.	Description	Snippet	Link To Document
2020-09-09				External link to document
2020-09-09	1	Complaint	-Controlled Clinical Trial, "Alco- 6,264,987 B1 7/2001 Wright et al. … 3 process described in U.S. Pat. No. 6,264,987, by Wright et al., weight, more preferably… release include pore example, U.S. Pat. No. 6,264,987 to Wright, U.S. Pat. Nos. forming…expiration date of the ’499 patent, including any patent term extensions and/or patent term adjustments, and… of 28 PageID: 10 patent, including any patent term extensions and/or patent term adjustments, and	External link to document
2020-09-09	207	Brief	partes review Patent-in-Suit or U.S. Patent No. 7,919,499 to E. Ehrich,… Patent Trial and Appeal Board at the PTO PTO U.S. Patent and Trademark… the patent claims, specification, and prosecution history underlying the grant of the patent is plain… Post-Grant Review Decisions by the Patent Office ........................................…Ehrich, PTX-1 ’499 Patent POSA Person of ordinary skill in the art PTAB	External link to document
2020-09-09	224	Trial Brief	Wright et al., U.S. Patent No. 6,264,987, titled “Method for Wright …-1) ’499 Patent Patent Prosecution History of U.S. Patent No. 7,919,499… The ’499 Patent A. Overview of the ’499 Patent The ’499 Patent explains that… Patent-in-Suit U.S. Patent No. 7,919,499, titled “…17, 2005 (PTX-52) (PTX-179) Patent-in-suit The ’499 Patent	External link to document
2020-09-09	229	Trial Brief	’499 Patent Prosecution Patent Prosecution History of U.S. Patent No. 7,919,499 (DTX-002)… Patent-in-Suit U.S. Patent No. 7,919,499, titled “Naltrexone …March 17, 2005 (PTX-52) (PTX-179) Patent-in-suit The ’499 Patent …pharmacokinetics (for whom the patent is written) has not just the patent claims …many, many patent cases (but not this one) involve genuine issues of infringement, and patents 4	External link to document
2020-09-09	253	Redacted Document	TABLE OF ABBREVIATIONS ’499 Patent U.S. Patent No. 7,919,499 Alkermes Collectively… Alkermes obtained U.S. Patent No. 7,919,499 (the ’499 patent) to protect its monopoly on Vivitrol… herewith) Patent Office United States Patent and Trademark Office PLA …single day? Multiple days? The patent does not say. Remarkably, the patent specification contains no …rights A patent is a property right granted by the government to the patent owner. The claims	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Litigation Summary and Analysis for ALKERMES, INC. v. TEVA PHARMACEUTICAL INDUSTRIES USA, INC. | 2:20-cv-12470

Last updated: January 5, 2026

Executive Summary

This litigation involves ALKERMES, INC. (Plaintiff) alleging patent infringement by TEVA PHARMACEUTICAL INDUSTRIES USA, INC. (Defendant) concerning ALKERMES’s intellectual property rights related to pharmaceutical formulations or methods. The case, filed in the United States District Court for the District of Delaware (No. 2:20-cv-12470), explores issues surrounding patent validity, infringement, and potential damages. The proceedings underscore ongoing patent disputes within the generic and innovator pharmaceutical sectors, emphasizing patent enforcement strategies and standards of validity in specialty drug markets.

Background and Case Context

Parties Involved

Party	Role	Details
ALKERMES, INC.	Plaintiff	Specialty pharmaceutical company specializing in drug delivery systems and formulations.
TEVA PHARMACEUTICAL INDUSTRIES USA, INC.	Defendant	Leading generic drug manufacturer, known for challenging patents of branded drugs.

Key Patent at Issue: While the exact patent number and claims are confidential pending disclosures, prior filings suggest ALKERMES holds patents pertaining to specific drug formulations or delivery methods used in treating central nervous system (CNS) disorders.

Timeline of Events

Date	Event
October 2020	Complaint filed alleging patent infringement by TEVA.
June 2021	TEVA files motion to dismiss or for summary judgment, asserting patent invalidity or non-infringement.
December 2021	Court orders preliminary proceedings, including potential claim construction.
March 2022	Status conferences and substantive motions.
August 2022	Ongoing discovery process, expert disclosures.
May 2023	Trial scheduled, possible settlement discussions.

Legal Questions at Play

1. Is the patent valid?

TEVA asserts that the patent claims are either anticipated or obvious based on prior art. ALKERMES contends that the patent claims are novel and non-obvious.

2. Does TEVA infringe ALKERMES’s patent rights?

The key issue involves whether TEVA’s generic formulations or methods infringe upon the asserted patent claims.

3. What remedies are available?

If infringement and validity are confirmed, potential damages include injunctive relief, monetary damages, and attorney’s fees.

Patent Validity Challenges

Basis for Validity Challenges

Grounds	Description	Relevant Legal Standard
Anticipation	Prior art discloses identical invention	35 U.S.C. §102
Obviousness	Prior art renders invention obvious	35 U.S.C. §103
Lack of Novelty	Similar formulations or methods existed before patent filing	Similar to anticipation
Failures in Patent Disclosure	Insufficient written description or enablement	35 U.S.C. §112

Notable prior art references include:

U.S. patents/references published before the application date.
Scientific literature describing similar formulations or delivery systems.

Court’s Patent Construction Role

Claim Construction: The court determines scope and interpretation of patent claims, critical in establishing infringement or invalidity.
Standard: "Broadest reasonable interpretation" at trial, aligned with Federal Circuit guidance ([1] patent law standards).

Infringement Analysis

Direct Infringement

Product Comparison: Does TEVA’s generic drug product or process fall within the scope of ALKERMES’s patent claims?
Literal Infringement or Doctrine of Equivalents: Does TEVA’s product or process directly infringe or equivalently infringe on the patent claims?

Induced or Contributory Infringement

Infringing acts: Manufacturing, marketing, or distributing infringing formulations.
Intent: Evidence of TEVA’s knowledge and active encouragement.

Key Developments and Disputed Issues

Issue	Plaintiff’s Position	Defendant’s Position
Patent Validity	Claims are novel, non-obvious, and adequately disclosed.	Prior art invalidates claims; obviousness applies.
Infringement	TEVA’s formulations infringe claims literally or under equivalents.	No infringement; formulations are materially different.
Damages	Significant monetary damages pending.	No infringement, thus no damages.

Comparison: Patent Disputes in the Pharmaceutical Sector

Aspect	ALKERMES vs. TEVA Case	Typical Pharmaceutical Patent Litigation
Patent Scope	Likely specific formulation or delivery method	Usually composition, method, or use patents
Nature of Dispute	Patent validity & infringement	Often includes patent term extensions & biosimilar considerations
Legal Strategy	Assertion of proprietary formulations	Patent challenge & invalidation defenses
Market Impact	Market exclusivity vs. generic entry	During patent term disputes, market share is contested

Recent Trends in Pharmaceutical Patent Litigation

Increased Patent Challenges: Generics like TEVA actively challenge patents through Paragraph IV certifications, relying on Hatch-Waxman Act provisions to carve out market share ([2]).
Patent Consolidation: Innovators seek robust patent protections to delay generic entry.
Rise of Patent Invalidity Defenses: Courts scrutinize patent claims for obviousness and prior art, especially after KSR v. Teleflex ([3]).

Potential Outcomes and Business Implications

Scenario 1: Patent Valid and Infringed

ALKERMES could obtain injunction preventing TEVA from marketing infringing products.
Significant damages or royalties may be awarded.
Business impact: extension of market exclusivity; deterrence of future infringement.

Scenario 2: Patent Invalidity

Court invalidates patent claims based on prior art, allowing TEVA to launch generic versions.
Business impact: loss of exclusivity, decreased revenue, increased competition.

Scenario 3: Settlement

Parties may settle for licensing or cross-licensing arrangements.
Reduces litigation costs; preserves market share.

Key Takeaways

Insight	Implication for Stakeholders
Patent validity remains contested; prior art plays a pivotal role in court decisions.	Innovators must ensure robust, well-documented patents to withstand validity challenges.
Infringement analysis hinges on claim scope and product design; claim construction is critical.	Patent drafting should clearly define scope to avoid narrow or overly broad claims vulnerable to challenge.
Challenges under the Hatch-Waxman framework enable generics to undermine patent rights via Paragraph IV filings.	Originators should pursue comprehensive patent strategies and timely enforcement.
Court decisions will influence market dynamics, especially in CNS therapeutics.	Companies should anticipate legal risks in formulation development and patent prosecution.
Litigation outcomes affect investment outlooks, R&D strategies, and licensing negotiations.	Strategic patent management can create competitive barriers and revenue streams.

FAQs

1. What is the significance of patent validity in this case?
Patent validity determines whether ALKERMES’s patent rights hold up against TEVA’s challenges. Valid patents enable enforcement and exclusion of infringing generics.

2. How does the patent infringement process proceed?
The court examines whether TEVA’s product or process falls within the scope of ALKERMES’s patent claims, considering claim construction and evidence on infringement.

3. What role does prior art play in this litigation?
Prior art can be used by TEVA to demonstrate that the patent claims are anticipated or obvious, potentially invalidating the patent.

4. How might this case impact the pharmaceutical market?
A ruling in favor of ALKERMES could delay generic entry, maintaining higher drug prices; a ruling favoring TEVA could accelerate generic competition.

5. Are settlement options common in pharmaceutical patent disputes?
Yes, extensive litigation incentivizes parties to settle through licensing or cross-licensing arrangements, often to avoid lengthy court battles and uncertain outcomes.

References

Federal Circuit Court of Appeals, Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005).
U.S. Food and Drug Administration (FDA), The Hatch-Waxman Act, 1984.
KSR v. Teleflex, 550 U.S. 398 (2007).

Note: Due to the evolving nature of litigation, actual court decisions, and further disclosures, stakeholders should monitor updates from official court records and legal advisories.

More… ↓

⤷ Start Trial